Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Leerink Partners Stick to Their Buy Rating for Mirati Therapeutics

Published 11/15/2021, 04:06 AM
Updated 11/15/2021, 04:06 AM


Leerink Partners analyst Andrew Berens maintained a Buy rating on Mirati Therapeutics (NASDAQ:MRTX) on Thursday, setting a price target of $205, which is approximately 44.11% above the present share price of $142.25.

Berens expects Mirati Therapeutics to post earnings per share (EPS) of -$1.55 for the fourth quarter of 2021.

The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Mirati Therapeutics, with an average price target of $219.67.
The analysts price targets range from a high of $300 to a low of $175.

In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $71.79 million and a net profit of -$79.5 million. The company's market cap is $7.37 billion.

According to TipRanks.com, Leerink Partners analyst Andrew Berens is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 5.2% and a 58.85% success rate.

Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.